May 6, 2026 04:05PM
Mar 12, 2026 04:05PM
Feb 12, 2026 07:30AM
Feb 12, 2026 07:30AM
Dec 24, 2025 06:00AM
Dec 24, 2025 06:00AM
Dec 8, 2025 02:52AM Lyell presents lymphoma trial data showing 93% response rate
Dec 7, 2025 04:30PM
Nov 12, 2025 04:05PM
Nov 10, 2025 07:30AM
Nov 10, 2025 07:30AM
Nov 3, 2025 09:00AM
Nov 3, 2025 09:00AM
Sep 3, 2025 08:00AM Lyell launches head-to-head CAR T-cell therapy trial in lymphoma
Sep 3, 2025 08:00AM
Aug 12, 2025 04:05PM
Jun 24, 2025 06:48AM
Jun 23, 2025 05:00PM
Jun 17, 2025 06:31AM
Jun 17, 2025 06:30AM
May 13, 2025 04:05PM Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
May 1, 2025 09:00AM
Apr 15, 2025 09:00AM
Apr 15, 2025 09:00AM
Mar 11, 2025 04:05PM
Jan 9, 2025 09:00AM
Dec 9, 2024 09:00PM
Nov 7, 2024 04:05PM Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024
Nov 5, 2024 09:30AM
Oct 24, 2024 04:00PM
Oct 24, 2024 04:00PM
Aug 7, 2024 04:05PM
Jun 26, 2024 07:02AM
Jun 26, 2024 07:00AM
Feb 28, 2024 04:05PM Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
Nov 9, 2023 04:05PM
Nov 8, 2022 04:05PM
Nov 8, 2022 04:05PM
Oct 6, 2022 04:05PM
Oct 6, 2022 04:05PM
Oct 6, 2022 04:05PM
May 10, 2022 04:05PM Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
May 10, 2022 04:05PM
Mar 29, 2022 04:05PM
Mar 29, 2022 04:05PM
Mar 8, 2022 04:45PM
Mar 8, 2022 04:45PM
Jan 24, 2022 08:05AM
Jan 24, 2022 08:00AM Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK
Jan 24, 2022 08:00AM

322,200 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All